Latest news
Grace Therapeutics (GRCE): Opaleye reports 2.75M-share, 13.07% ownership stake - Stock TitanStock Titan · Fri, 07 Aug 2026 20:06:08 GMTGrace Therapeutics Expects Funding to Extend Cash Runway Through 2028 - Stock TitanStock Titan · Wed, 05 Aug 2026 03:43:14 GMTGrace Therapeutics Announces $10 Million Private Placement Financing to Support GTx-104 Development - Quiver QuantitativeQuiver Quantitative · Wed, 05 Aug 2026 01:10:00 GMTGrace Therapeutics, Inc. announced that it expects to receive $9.999998 million in funding - marketscreener.commarketscreener.com · Mon, 03 Aug 2026 22:00:00 GMTContext Therapeutics (NASDAQ: CNTX) faces Nasdaq minimum bid-price deficiency risk - Stock TitanStock Titan · Fri, 31 Jul 2026 20:09:45 GMTGrace Therapeutics Receives Type a Meeting Minutes from FDA and Provides Update on GTx-104 Clinical-Stage Injectable Formulation - marketscreener.commarketscreener.com · Tue, 28 Jul 2026 13:08:20 GMTGrace Therapeutics Advances Second U.S. Manufacturing Route for GTx-104 - Stock TitanStock Titan · Tue, 28 Jul 2026 07:00:00 GMTGrace Therapeutics Says FDA Minutes Confirm No Clinical Safety or Efficacy Deficiencies in GTx-104 Review, Advances Dual-Source Manufacturing Plan Toward NDA Resubmission - Quiver QuantitativeQuiver Quantitative · Tue, 28 Jul 2026 07:00:00 GMT